CytomX Therapeutics Inc (NASDAQ: CTMX) is -24.52% lower on its value in year-to-date trading and has touched a low of $1.04 and a high of $5.85 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CTMX stock was last observed hovering at around $1.19 in the last trading session, with the day’s loss setting it -0.02%.
Currently trading at $1.17, the stock is -2.86% and -7.30% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.6 million and changing -1.68% at the moment leaves the stock -30.71% off its SMA200. CTMX registered -7.14% loss for a year compared to 6-month loss of -44.55%. The firm has a 50-day simple moving average (SMA 50) of $1.2554 and a 200-day simple moving average (SMA200) of $1.6871.
The stock witnessed a -1.68% gain in the last 1 month and extending the period to 3 months gives it a -3.31%, and is -1.68% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.90% over the week and 6.35% over the month.
CytomX Therapeutics Inc (CTMX) has around 122 employees, a market worth around $91.40M and $119.57M in sales. Current P/E ratio is 8.40. Profit margin for the company is 9.27%. Distance from 52-week low is 12.50% and -80.00% from its 52-week high.
CytomX Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -0.17 with sales reaching $17.51M over the same period.The EPS is expected to shrink by -3053.00% this year, but quarterly earnings will post -0.00% year-over-year. Quarterly sales are estimated to grow 23.80% in year-over-year returns.
86.0 institutions hold shares in CytomX Therapeutics Inc (CTMX), with institutional investors hold 72.99% of the company’s shares. The shares outstanding are 78.12M, and float is at 76.79M with Short Float at 9.09%. Institutions hold 72.26% of the Float.
The top institutional shareholder in the company is TANG CAPITAL MANAGEMENT LLC with over 7.79 million shares valued at $9.51 million. The investor’s holdings represent 9.4989 of the CTMX Shares outstanding. As of 2024-06-30, the second largest holder is JANUS HENDERSON GROUP PLC with 6.3 million shares valued at $7.72 million to account for 7.6826 of the shares outstanding. The other top investors are BVF INC/IL which holds 5.23 million shares representing 6.3739 and valued at over $6.38 million, while VANGUARD GROUP INC holds 5.9641 of the shares totaling 4.89 million with a market value of $5.97 million.
CytomX Therapeutics Inc (CTMX) Insider Activity
The most recent transaction is an insider sale by Landau Jeffrey B, the company’s Chief Business Officer. SEC filings show that Landau Jeffrey B sold 4,181 shares of the company’s common stock on Aug 20 ’24 at a price of $1.23 per share for a total of $5139.0. Following the sale, the insider now owns 0.12 million shares.
CytomX Therapeutics Inc disclosed in a document filed with the SEC on Aug 20 ’24 that BELVIN MARCIA (SVP, Chief Scientific Officer) sold a total of 4,181 shares of the company’s common stock. The trade occurred on Aug 20 ’24 and was made at $1.23 per share for $5139.0. Following the transaction, the insider now directly holds 0.18 million shares of the CTMX stock.
Still, SEC filings show that on Aug 20 ’24, ROWLAND LLOYD A (General Counsel) disposed off 4,181 shares at an average price of $1.23 for $5139.0. The insider now directly holds 130,797 shares of CytomX Therapeutics Inc (CTMX).
